Searchable abstracts of presentations at key conferences in endocrinology

ea0029p709 | Diabetes | ICEECE2012

Safety and efficacy of linagliptin in type 2 diabetes (T2D) patients (pts) with common renal and cardiovascular risk factors

von Eynatten M. , Gong Y. , Emser A. , Woerle H.

Introduction: Vascular complications are the leading cause of morbidity and mortality in T2D. Hypertension and/or microalbuminuria predict renal and cardiovascular outcome. This large pooled analysis from a global development program aimed to evaluate the safety and efficacy of linagliptin in this particularly high-risk population.Methods: Data of 1982 pts from 3 randomized, double-blind, placebo(PBO)-controlled phase 3 trials were analyzed. Pts with mic...